Why the study?
Does TAVI improve clinical outcomes in patients with severe co-morbidities and low-flow, low-gradient aortic stenosis?
Does TAVI improve clinical outcomes in patients with severe co-morbidities and low-flow, low-gradient aortic stenosis?
TAVI is feasible and provides symptomatic and functional benefits in survivors with low-flow, low-gradient aortic stenosis and severe comorbidities, despite high early mortality.
Answers are grounded in this paper and cite their sources.
High early mortality warrants caution in selection; leaves open symptomatic benefit of TAVI in comorbid low-flow, low-gradient aortic stenosis.
Our study suggests that TAVI is feasible in patients with severe co-morbidities and low-flow, low-gradient aortic stenosis. Within the first 6 months after treatment all-cause mortality was considerable high, but the surviving patients showed symptomatic benefit and significant improvement of myocardial function and exercise capacity.
No takes yet. Share an insight, caveat, or question.
Gotzmann et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: